-1 |BT| (ROOT (S (S (VP (VBG Blocking) (SBAR (S (NP (NP (NP (DT either) (JJ nicotinic) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP hexamethonium) (QP (CD 200) (CD µM))) (-RRB- -RRB-))) (CC or) (NP (NP (CD 5-HT)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)))) (VP (VBD receptors) (S (-LRB- -LRB-) (NP (JJ granisetron) (CD 1) (NN µM)) (-RRB- -RRB-) (ADVP (RB together))) (PP (IN with) (NP (CD P2) (NNS receptors)))))))) (VP (VBD had) (NP (DT no) (JJR greater) (NN effect)) (PP (IN than) (S (VP (VBG blocking) (NP (CD P2) (NNS receptors)) (ADVP (RB alone)))))) (. .))) |ET| |BV| 1:-0.25729548931121826 2:-0.60757321119308472 3:0.25531035661697388 4:-0.2128010094165802 5:-0.1836087554693222 6:0.15599599480628967 7:0.3855879008769989 8:0.15595799684524536 9:0.40101087093353271 10:1.1379938125610352 11:0.24072727560997009 12:0.45316481590270996 13:0.12644676864147186 14:-0.6767265796661377 15:-1.077654242515564 16:0.55234169960021973 17:0.1855442076921463 18:-0.62255626916885376 19:-0.085342012345790863 20:-0.26921311020851135 21:-0.66024971008300781 22:-0.88547837734222412 23:0.24518170952796936 24:-0.75918763875961304 25:0.14363175630569458 26:0.23287642002105713 27:0.63365274667739868 28:0.70826655626296997 29:0.75764846801757812 30:0.23826737701892853 31:1.08797287940979 32:-0.60845452547073364 33:0.79747074842453003 34:-0.72997963428497314 35:-0.63470244407653809 36:-0.0032161271665245295 37:-0.44317424297332764 38:0.041561700403690338 39:1.4241386651992798 40:0.4453660249710083 41:-0.305226 42:-0.13047078 43:-0.038385343 44:-0.22101413 45:0.59887439 46:-0.40105897 47:-0.37848315 48:-0.24854353 49:-0.51252002 50:0.68771392 51:0.60227454 52:-0.43584502 53:-0.0006715341 54:-0.17153397 55:-0.52105951 56:0.49241221 57:-0.20209827 58:-0.29198954 59:-0.044700895 60:-0.17758502  |EV|
-1 |BT| (ROOT (S (NP (NP (NNP Benlysta)) (PRN (-LRB- -LRB-) (NP (NN belimumab)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB fully) (JJ human)) (JJ recombinant) (NN monoclonal) (NN IgG) (NN antibody)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ neutralizes) (NP (JJ soluble) (JJ B-lymphocyte) (NN stimulator))) (CC and) (VP (VBZ inhibits) (NP (PRP$ its) (JJ biologic) (NN activity)))))))) (. .))) |ET| |BV| 1:-0.56537109613418579 2:-0.51021510362625122 3:0.44587022066116333 4:0.2158963680267334 5:-1.083593487739563 6:0.050816841423511505 7:0.45344507694244385 8:0.27028200030326843 9:-0.37541112303733826 10:-0.47644007205963135 11:0.1290128082036972 12:0.0050708581693470478 13:0.26641273498535156 14:1.1709394454956055 15:0.033012617379426956 16:-0.97627627849578857 17:-0.0011830794392153621 18:-0.30612841248512268 19:0.88903170824050903 20:-0.47036188840866089 21:-0.11961361765861511 22:-0.22607925534248352 23:0.58062535524368286 24:-0.076213471591472626 25:-0.53149330615997314 26:0.71904027462005615 27:1.0224469900131226 28:-0.49678796529769897 29:-0.25860661268234253 30:-0.33419641852378845 31:-0.50046861171722412 32:0.22018571197986603 33:-0.027223262935876846 34:0.94427061080932617 35:0.81768244504928589 36:-0.84999847412109375 37:-0.12441810965538025 38:-0.50189703702926636 39:1.1623958349227905 40:-1.0994398593902588 41:-0.36144519 42:-0.25001836 43:0.16648084 44:-0.041238517 45:-0.40602309 46:-0.25899443 47:-0.22407059 48:-0.0093594883 49:0.075870238 50:0.20465884 51:0.51498497 52:0.028525867 53:0.083436906 54:0.20669249 55:-0.096456237 56:0.075422369 57:0.29807958 58:0.019806743 59:-0.11485586 60:0.033812765  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Peptide) (NN fusion) (NNS inhibitors)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (NNP T20)) (PRN (-LRB- -LRB-) (NP (NNP Fuzeon)) (, ,) (NP (NN enfuvirtide)) (-RRB- -RRB-))) (CC and) (NP (NNP C34)))) (, ,)) (VP (VBP interact) (PP (IN with) (NP (NP (DT the) (JJ N-terminal) (JJ heptad) (NN repeat)) (PP (IN of) (NP (NP (NP (JJ human) (NN immunodeficiency) (NN virus)) (ADJP (NN type) (CD 1))) (PRN (-LRB- -LRB-) (NP (NNP HIV-1)) (-RRB- -RRB-)))))) (NP (JJ gp41) (NN glycoprotein) (S (VP (TO to) (VP (VB form) (NP (NP (DT an) (JJ inactive) (JJ hetero) (JJ six-helix) (NN bundle)) (PRN (-LRB- -LRB-) (NP (CD 6-HB)) (-RRB- -RRB-))))))) (S (VP (TO to) (VP (VB prevent) (NP (NP (NNP HIV-1) (NN infection)) (PP (IN of) (NP (NN host) (NNS cells)))))))) (. .))) |ET| |BV| 1:-0.0077140997163951397 2:-0.33000063896179199 3:1.1667492389678955 4:-0.2471356987953186 5:0.57900947332382202 6:-0.75803923606872559 7:-0.54675149917602539 8:0.72856897115707397 9:-0.45677205920219421 10:-0.0068537336774170399 11:-0.41488343477249146 12:0.44791659712791443 13:0.64409887790679932 14:0.30772566795349121 15:-0.38658693432807922 16:-0.83080685138702393 17:-0.60835391283035278 18:-0.13659399747848511 19:1.3188679218292236 20:-1.0010696649551392 21:-0.36609500646591187 22:-1.1811347007751465 23:1.2298450469970703 24:-0.063506990671157837 25:0.65311241149902344 26:-1.1658190488815308 27:-0.35198488831520081 28:1.1011252403259277 29:-0.25958159565925598 30:-0.18539613485336304 31:0.092284873127937317 32:0.56663936376571655 33:0.53070569038391113 34:-0.050940200686454773 35:-0.66351526975631714 36:-0.40273794531822205 37:-0.42771682143211365 38:-0.32982331514358521 39:1.1934760808944702 40:-0.50245857238769531 41:0.062623098 42:-0.19988714 43:-0.26141369 44:-0.49916357 45:0.01225979 46:-0.65415329 47:0.022658471 48:-0.0666449 49:0.48808017 50:0.080611236 51:0.83366996 52:0.36037317 53:0.039276369 54:0.019118777 55:0.039003458 56:0.32407039 57:-0.12864597 58:-0.032875348 59:-0.23659243 60:-0.11443043  |EV|
-1 |BT| (ROOT (S (PP (IN In) (NP (NN general))) (, ,) (NP (NP (DT the) (JJR higher) (NN dose)) (PP (IN of) (NP (NNP Mg)))) (VP (VBD was) (ADJP (RBR more) (JJ effective)) (PP (IN than) (NP (DT the) (JJR lower) (NN dose))) (PP (IN in) (S (VP (VP (VBG ameliorating) (NP (NP (JJ creatine) (JJ kinase-MB) (NN elevation)) (CC and) (NP (NP (DT the) (NN state)) (PP (IN of) (NP (NP (JJ oxidative) (NN stress)) (, ,) (NP (NP (JJ lactate) (NN accumulation)) (, ,) (NP (JJ pyruvate) (NN reduction)))))))) (CONJP (RB as) (RB well) (IN as)) (VP (VBG preserving) (NP (NP (JJ creatine) (NN phosphate)) (, ,) (NP (JJ adenine) (NNS nucleotides)) (CC and) (NP (NP (NNP Na)) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (NNP K)) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (: -) (NP (JJ ATPase) (NN activity)))) (. .))) |ET| |BV| 1:-0.98417937755584717 2:0.41805446147918701 3:0.35911783576011658 4:-0.893424391746521 5:-0.28451302647590637 6:-0.78242135047912598 7:-0.58465123176574707 8:0.97099947929382324 9:0.19545634090900421 10:-1.824374794960022 11:-0.0024916052352637053 12:0.65486383438110352 13:0.18116830289363861 14:1.189051628112793 15:-0.096406184136867523 16:-0.96060627698898315 17:-0.53619104623794556 18:-0.27410814166069031 19:-0.029814116656780243 20:-1.4676651954650879 21:-0.45950323343276978 22:0.82897645235061646 23:-0.37338608503341675 24:0.29901552200317383 25:-0.43127813935279846 26:-1.3269736766815186 27:-0.063472636044025421 28:0.56292855739593506 29:-0.60502159595489502 30:-0.0088812140747904778 31:-0.50334703922271729 32:0.93427449464797974 33:1.2102525234222412 34:0.29457369446754456 35:-0.44242003560066223 36:-0.523673415184021 37:-0.25843331217765808 38:-0.13381807506084442 39:0.083229199051856995 40:-0.78091228008270264 41:-0.39301157 42:0.44586915 43:-0.039535813 44:0.059341788 45:0.0038114588 46:-0.054295007 47:0.13249013 48:0.12430164 49:0.23482861 50:-0.10492339 51:0.31854078 52:-0.074567154 53:0.48042464 54:-0.40591514 55:-0.20545575 56:-0.21593638 57:0.19447657 58:0.70825106 59:0.51994342 60:0.088790596  |EV|
-1 |BT| (ROOT (S (NP (DT The) (JJ systematic) (NN review)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT a) (JJ 5-day) (NN course)) (PP (IN of) (NP (NP (NNP Azithromycin)) (PP (IN with) (NP (NNP Scaling) (CC and) (NNP Root) (NNP Planing)))))) (VP (VBZ reduces) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (JJ gingival) (NN overgrowth)))) (, ,) (SBAR (IN while) (S (NP (NP (DT a) (JJ 7-day) (NN course)) (PP (IN of) (NP (NN metronidazole)))) (VP (VBZ is) (ADJP (RB only) (JJ effective) (PP (IN on) (NP (JJ concomitant) (JJ bacterial) (NN over-infection))))))))))) (. .))) |ET| |BV| 1:0.69746941328048706 2:0.23325002193450928 3:-0.026372672989964485 4:0.10488508641719818 5:0.062258489429950714 6:-0.72683560848236084 7:0.4975840151309967 8:-0.21602946519851685 9:0.027523573487997055 10:0.9229467511177063 11:-0.68019992113113403 12:-0.18124848604202271 13:-0.699177086353302 14:0.44120791554450989 15:-0.47514113783836365 16:0.50658750534057617 17:0.25434038043022156 18:0.71095836162567139 19:0.95728021860122681 20:0.63920068740844727 21:0.55857408046722412 22:-0.68155378103256226 23:-0.43861976265907288 24:0.88641625642776489 25:1.3793158531188965 26:0.25084564089775085 27:0.37498617172241211 28:0.77558702230453491 29:0.026136936619877815 30:0.072375580668449402 31:-0.71559768915176392 32:-0.37849581241607666 33:0.93434333801269531 34:2.0973701477050781 35:0.49652671813964844 36:-0.42280656099319458 37:-0.58269280195236206 38:1.0277420282363892 39:-0.71642023324966431 40:0.91448080539703369 41:-0.042760674 42:0.005793212 43:-0.27699929 44:0.37065974 45:0.36340979 46:-0.12599862 47:0.56844074 48:-0.017184172 49:0.24642904 50:0.28509822 51:0.30643809 52:-0.006117322 53:-0.42155811 54:-0.40517884 55:0.16639504 56:0.054007974 57:0.71698523 58:-0.035324737 59:0.26002467 60:-0.18624085  |EV|
-1 |BT| (ROOT (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (JJ low) (JJ molecular) (NN weight) (NN heparin)) (PP (CC plus) (NP (NN aspirin)))))) (VP (VBZ remains) (NP (NN unproven)) (, ,) (S (VP (VBG highlighting) (NP (DT the) (JJ urgent) (NN need)) (PP (IN for) (NP (JJ large) (JJ controlled) (NNS trials)))))) (. .))) |ET| |BV| 1:-0.4122677743434906 2:-0.46324244141578674 3:0.073631599545478821 4:-0.10951337963342667 5:0.16933341324329376 6:-0.27944037318229675 7:-0.18100021779537201 8:-0.50181663036346436 9:0.24505071341991425 10:0.34632956981658936 11:-0.46979761123657227 12:0.0045941001735627651 13:-0.65328466892242432 14:-0.18240880966186523 15:0.043888773769140244 16:0.63524508476257324 17:-0.069035768508911133 18:0.38571858406066895 19:0.22889822721481323 20:-0.57725471258163452 21:-0.45031630992889404 22:0.15654109418392181 23:-0.1405574232339859 24:0.57517284154891968 25:0.19980970025062561 26:-0.0032609140034765005 27:-0.33045914769172668 28:-0.79845482110977173 29:0.21623410284519196 30:-0.19117653369903564 31:-0.26789900660514832 32:0.13184972107410431 33:0.56898230314254761 34:-0.53675496578216553 35:-0.2580471932888031 36:0.65332514047622681 37:-0.48971584439277649 38:-0.86091041564941406 39:0.14939133822917938 40:-0.010001880116760731 41:0.17688897 42:0.15450206 43:-0.026334198 44:0.0098177642 45:0.45932305 46:-0.05749698 47:-0.23299187 48:-0.64532 49:0.44631541 50:0.18884619 51:0.41021365 52:-0.028410416 53:-0.013899116 54:0.337699 55:0.37197608 56:0.16116959 57:0.025267078 58:-0.096162207 59:-0.15528823 60:0.074057989  |EV|
-1 |BT| (ROOT (S (S (NP (DT This) (NNP SSAT1) (NN effect)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN attributed) (PP (TO to) (NP (NP (NP (DT the) (NN depletion)) (PP (IN of) (NP (JJ overall) (JJ cellular) (NNS polyamines)))) (CC or) (NP (NP (NP (NN accumulation)) (PP (IN of) (NP (NP (NNP N)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))))) (: -) (NP (NP (NP (NN acetylspermidine)) (-LRB- -LRB-) (NP (NP (NP (NNP N)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (: -) (NP (NNP AcSpd))) (-RRB- -RRB-)) (PP (RB because) (IN of) (NP (DT the) (NN following)))) (: :) (NP (NP (-LRB- -LRB-) (JJ i) (-RRB- -RRB-) (NN addition)) (PP (IN of) (NP (NP (NN putrescine) (, ,) (NN spermidine) (, ,) (NN spermine) (, ,) (CC or) (NN N)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)))))))))))) (: -) (S (NP (NNP AcSpd)) (VP (VBD did) (RB not) (VP (VB restore) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNP GFP) (CC or) (NNP GFP-eIF5A))))))) (: ;) (S (NP (NP (NP (-LRB- -LRB-) (JJ ii) (-RRB- -RRB-) (NN depletion)) (PP (IN of) (NP (NP (JJ cellular) (NNS polyamines)) (PP (IN with) (NP (NN alpha-difluoromethylornithine)))))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (JJ ornithine) (NN decarboxylase)))) (, ,)) (VP (VBD did) (RB not) (VP (VB inhibit) (NP (NP (JJ exogenous) (NN gene) (NN expression)) (: ;) (CC and) (PRN (-LRB- -LRB-) (VP (VBN iii)) (-RRB- -RRB-)) (NP (NP (NNP N)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (, ,) (NP (NP (NNP N)) (PRN (-LRB- -LRB-) (NP (CD 11)) (-RRB- -RRB-)))))))) (: -) (S (NP (NP (NN bis)) (PRN (-LRB- -LRB-) (ADJP (JJ ethyl)) (-RRB- -RRB-))) (VP (VP (ADVP (RB norspermine)) (VBD caused) (NP (NP (DT a) (JJ drastic) (NN depletion)) (PP (IN of) (NP (JJ cellular) (NNS polyamines)))) (PP (IN through) (NP (NP (NN induction)) (PP (IN of) (NP (JJ endogenous) (NN SSAT1)))))) (CC but) (VP (VBD did) (RB not) (VP (VB block) (NP (JJ exogenous) (NN gene) (NN expression)))))) (. .))) |ET| |BV| 1:-0.90909707546234131 2:-0.4379083514213562 3:1.3501079082489014 4:-1.3608216047286987 5:0.081174321472644806 6:-0.21249093115329742 7:-1.0717818737030029 8:0.80661725997924805 9:-0.76155024766921997 10:0.22594225406646729 11:1.2293902635574341 12:0.55379337072372437 13:-0.024003908038139343 14:-0.59998881816864014 15:-0.59560304880142212 16:0.64742386341094971 17:0.17508698999881744 18:0.9019884467124939 19:0.77773487567901611 20:-1.8298786878585815 21:-0.20879268646240234 22:-0.49930450320243835 23:1.4011268615722656 24:-1.0873476266860962 25:0.24766780436038971 26:-0.66021835803985596 27:-0.34476840496063232 28:2.7371506690979004 29:0.49598237872123718 30:-0.36735615134239197 31:-0.26833125948905945 32:-0.65613627433776855 33:0.17522504925727844 34:-1.0836693048477173 35:-0.7465481162071228 36:0.56513041257858276 37:-0.099093548953533173 38:0.4945627748966217 39:0.10047130286693573 40:-2.22994065284729 41:-0.23483682 42:-0.72025871 43:0.39285842 44:-0.49433208 45:-0.8647055 46:-0.74018657 47:-0.01792649 48:-0.0170459 49:-0.55552799 50:0.11956397 51:0.73829073 52:-0.40209806 53:-0.25534898 54:-0.47646815 55:-0.28588906 56:0.72191691 57:-0.21502535 58:-0.44799978 59:0.46788076 60:0.19416445  |EV|
-1 |BT| (ROOT (S (PP (IN In) (NP (DT the) (NN liver))) (, ,) (NP (NNP AFB1)) (VP (VP (VBD inhibited) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (JJ superoxide) (ADJP (JJ dismutase) (CC and) (JJ glutathione)) (NN peroxidase)) (PRN (-LRB- -LRB-) (NP (NP (NNP C40) (CC and) (NNP C60)) (: ;) (NP (NNP P) (NNP <) (NNP 0.05))) (-RRB- -RRB-)))))) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN content)) (PP (IN of) (NP (NP (NP (NN malonaldehyde)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NNP C40) (CC and) (NNP C60))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBN induced) (NP (DT the) (NN damage)) (PP (IN in) (NP (DT the) (NN liver) (CC and) (NN kidney))) (SBAR (IN as) (S (VP (VBN shown) (PP (IN in) (NP (NP (DT the) (NNS photomicrographs)) (PP (IN of) (NP (JJ hematoxylin) (CC and) (JJ eosin-stained) (NNS sections)))))))))))))))) (. .))) |ET| |BV| 1:-1.7206878662109375 2:0.91427451372146606 3:0.86343115568161011 4:-0.56039834022521973 5:-0.7393791675567627 6:-0.47360557317733765 7:-0.32320672273635864 8:0.46104916930198669 9:-0.11539750546216965 10:0.78137010335922241 11:0.020228339359164238 12:-0.097153432667255402 13:1.155964732170105 14:0.15880197286605835 15:-0.089633725583553314 16:-1.3297442197799683 17:-1.6631003618240356 18:-0.52928012609481812 19:0.28385847806930542 20:-0.98094969987869263 21:-1.7904626131057739 22:0.92699247598648071 23:1.1614391803741455 24:-0.40715929865837097 25:-0.7838248610496521 26:0.47215729951858521 27:-0.36817920207977295 28:0.32590970396995544 29:-1.1977100372314453 30:-0.22816437482833862 31:0.88010859489440918 32:0.22562092542648315 33:0.026794567704200745 34:0.53224629163742065 35:-0.50178474187850952 36:0.073590584099292755 37:-0.78106743097305298 38:0.48515874147415161 39:0.48410341143608093 40:-0.12974515557289124 41:-0.26120588 42:-0.5952028 43:0.21596184 44:0.14572035 45:-0.2909911 46:-0.18164939 47:0.13423532 48:0.21788581 49:0.1059583 50:-0.11459617 51:0.49376917 52:-0.20878731 53:0.40687075 54:-0.53586131 55:0.20169598 56:0.3145631 57:0.41238254 58:-0.04609197 59:-0.072156854 60:0.084981672  |EV|
-1 |BT| (ROOT (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB therefore)) (, ,) (SBAR (SBAR (S (VP (VBD concluded) (SBAR (IN that) (S (NP (NNS trypanosomosis)) (VP (MD can) (VP (VB cause) (NP (JJ serious) (NN infertility)) (PP (IN in) (NP (JJ male) (JJ red) (JJ fronted) (NNS gazelles)))))))))) (CC and) (SBAR (IN that) (S (NP (NP (JJ early) (NNS treatments)) (PP (IN with) (NP (JJ melarsamine) (NN hydrochloride))) (PRN (-LRB- -LRB-) (NP (NNP Cymelarsan) (NNP ®)) (-RRB- -RRB-)) (PP (IN at) (NP (NP (CD 0.3) (CC and) (CD 0.6)) (VP (VBG mg/kg) (NP (NP (NP (NN body) (NN weight) (CC or) (NN diminazene) (NN aceturate)) (PRN (-LRB- -LRB-) (NP (NNP Berenil) (NNP ®)) (-RRB- -RRB-))) (PP (IN at) (NP (CD 7.0) (NN mg/kg) (NN body) (NN weight)))))))) (VP (MD may) (VP (VB prevent) (NP (JJ such) (NNS effects)))))))) (. .))) |ET| |BV| 1:-1.5407097339630127 2:-0.92629194259643555 3:-0.3774828314781189 4:-0.754283607006073 5:-0.72625935077667236 6:0.10090284794569016 7:-0.88309931755065918 8:-0.92627495527267456 9:-1.0576647520065308 10:-0.58284354209899902 11:-0.73703235387802124 12:1.4812121391296387 13:-0.013072089292109013 14:0.92986863851547241 15:-1.0461180210113525 16:-0.36540958285331726 17:-0.55455011129379272 18:-0.43936198949813843 19:-0.22077715396881104 20:0.12817886471748352 21:-1.3817523717880249 22:-1.0762064456939697 23:0.65246343612670898 24:-1.0126488208770752 25:-0.24642230570316315 26:0.43497449159622192 27:-0.75312793254852295 28:-0.87296599149703979 29:-0.81173509359359741 30:-0.78478658199310303 31:-0.60591918230056763 32:1.0628787279129028 33:0.72632235288619995 34:-0.019803080707788467 35:-0.6135934591293335 36:-0.46820095181465149 37:-1.1641658544540405 38:-0.24296721816062927 39:0.44465965032577515 40:-0.54818391799926758 41:-0.32333848 42:0.031465132 43:0.15002017 44:-0.28619036 45:0.24132143 46:-0.23290233 47:-0.01000658 48:-0.35536692 49:-0.074204989 50:0.18165582 51:0.18442251 52:0.20525627 53:0.30434346 54:0.53793764 55:0.305172 56:0.054813579 57:0.2040846 58:0.041628659 59:0.30880833 60:0.032141797  |EV|
-1 |BT| (ROOT (NP (NP (NP (NNP Treatment)) (PP (IN of) (NP (NP (JJ asymptomatic) (NNS carriers)) (PP (IN with) (NP (NN artemether-lumefantrine)))))) (: :) (NP (DT an) (NN opportunity) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (NN burden)) (PP (IN of) (NP (NN malaria)))))))) (. ?))) |ET| |BV| 1:-1.1312375068664551 2:-0.81061857938766479 3:0.37586134672164917 4:-0.60280418395996094 5:1.1493836641311646 6:0.015616275370121002 7:-0.36189296841621399 8:-0.38610804080963135 9:0.88122326135635376 10:1.2495263814926147 11:-1.4674458503723145 12:0.11047765612602234 13:-1.2778183221817017 14:-0.19230344891548157 15:0.39309293031692505 16:0.8717227578163147 17:-0.53200167417526245 18:-1.12095046043396 19:0.14850395917892456 20:-0.31582090258598328 21:-0.5805622935295105 22:-0.22375732660293579 23:0.16768859326839447 24:-0.018564170226454735 25:-0.13458013534545898 26:-1.1953909397125244 27:-0.69077873229980469 28:1.358599066734314 29:0.37121975421905518 30:0.94995242357254028 31:-1.2877407073974609 32:0.24666973948478699 33:0.97979551553726196 34:-0.50443613529205322 35:-0.99266344308853149 36:-0.91258573532104492 37:0.037456389516592026 38:1.0946654081344604 39:0.11811016499996185 40:-1.2569296360015869 41:-0.0057172808 42:-0.024811186 43:-0.0013002461 44:0.0096538616 45:-0.024962649 46:0.022070877 47:0.0059382655 48:0.017953787 49:0.023422506 50:0.012781125 51:-0.01201088 52:-0.012310849 53:0.017625935 54:-0.020087145 55:0.012457847 56:0.022369802 57:0.014889893 58:0.0017461845 59:-0.0055142133 60:-0.019485498  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP BACKGROUND)) (: :) (S (PP (IN In) (NP (JJ virologically) (JJ suppressed) (NNS patients))) (, ,) (NP (NP (NN switching)) (PP (TO to) (NP (NP (NN darunavir/ritonavir)) (PRN (-LRB- -LRB-) (NP (NNP DRV/r)) (-RRB- -RRB-))))) (VP (VP (ADVP (RB monotherapy)) (VBZ maintains) (NP (NNP HIV) (NNP RNA) (NNP suppression))) (, ,) (CC and) (VP (MD could) (ADVP (RB also)) (VP (VB lower) (NP (NN treatment) (NNS costs)))))) (. .))) |ET| |BV| 21:-1.4446250200271606 22:-0.4934391975402832 23:0.3028901219367981 24:0.098139896988868713 25:-0.084036901593208313 26:-0.60067528486251831 27:-0.045485895127058029 28:-0.20654243230819702 29:-0.25986936688423157 30:0.44161754846572876 31:-0.53373360633850098 32:-0.044802453368902206 33:0.69945645332336426 34:0.23874844610691071 35:-0.098392784595489502 36:0.19838865101337433 37:-0.83548247814178467 38:0.0063304346986114979 39:0.9234660267829895 40:-0.050698824226856232 41:-0.12388024 42:0.25113642 43:-0.21239717 44:-0.02534309 45:-0.0027524375 46:0.11156775 47:-0.15308137 48:-0.10400744 49:0.08963073 50:0.24862568 51:0.25476357 52:-0.24146292 53:0.14951187 54:0.15793042 55:0.069327243 56:-0.0039202776 57:0.33811569 58:0.54153299 59:0.39957628 60:-0.51824892  |EV|
-1 |BT| (ROOT (S (NP (DT The) (JJ metabolite) (NNS changes)) (VP (VBD observed) (PP (IN in) (NP (NNP PHYAOX) (NNS leaves))) (, ,) (ADVP (RB together)) (PP (IN with) (NP (DT those))) (PP (IN in) (NP (NP (DT the) (NN source)) (VP (VBZ leaves)))) (, ,) (VP (VBN identified) (NP (NP (JJ possible) (NNS candidates)) (PP (IN for) (NP (NP (DT the) (JJ metabolite) (NN signature)) (PRN (-LRB- -LRB-) (NP (NP (NNP e.g.)) (, ,) (NP (CD 2-oxo-glutarate) (, ,) (NN spermidine) (, ,) (NN putrescine) (, ,) (NN 4-amino-butyrate) (, ,) (CC and) (NN tryptophan))) (-RRB- -RRB-))))) (PP (IN during) (NP (NP (JJ short-day-induced) (NN growth) (NN cessation)) (PP (IN in) (NP (NN aspen) (NNS leaves))))))) (. .))) |ET| |BV| 1:-0.20879268646240234 2:-0.49930450320243835 3:1.4011268615722656 4:-1.0873476266860962 5:0.24766780436038971 6:-0.66021835803985596 7:-0.34476840496063232 8:2.7371506690979004 9:0.49598237872123718 10:-0.36735615134239197 11:-0.26833125948905945 12:-0.65613627433776855 13:0.17522504925727844 14:-1.0836693048477173 15:-0.7465481162071228 16:0.56513041257858276 17:-0.099093548953533173 18:0.4945627748966217 19:0.10047130286693573 20:-2.22994065284729 21:-0.25488251447677612 22:-0.25510013103485107 23:0.80422317981719971 24:-0.92508947849273682 25:0.14783799648284912 26:-2.0449709892272949 27:-0.92972677946090698 28:1.9645959138870239 29:-0.61361336708068848 30:-0.68767958879470825 31:0.59816557168960571 32:-0.58688026666641235 33:0.019019341096282005 34:0.063053913414478302 35:-0.38321271538734436 36:0.87058103084564209 37:0.010515990667045116 38:1.0598834753036499 39:0.83497476577758789 40:-1.7930039167404175 41:-0.4742955 42:0.13303316 43:0.17753239 44:-0.086967781 45:0.31425694 46:0.099542491 47:0.69735318 48:-0.023919899 49:0.16898106 50:-0.19517796 51:0.66799968 52:-0.15761472 53:0.33587563 54:-0.084976837 55:0.38962021 56:0.18236293 57:0.021945056 58:0.18385154 59:0.48538375 60:0.0077088871  |EV|
-1 |BT| (ROOT (S (ADVP (RB Similarly)) (, ,) (NP (NP (DT the) (JJ average) (JJ tramadol) (NN consumption)) (PP (IN at) (NP (NNS hours) (CD 24) (CC and) (CD 48)))) (VP (VBD was) (ADJP (RB significantly) (JJR lower)) (PP (IN for) (NP (NP (DT the) (JJ cholestyramine) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD 5.32) (NNP ±) (CD 21.45)) (PP (IN vs.) (NP (QP (CD 43.18) (CD ±)) (NP (NP (CD 61.56) (NN mg)) (PP (IN at) (NP (CD 24) (NN h)))) (, ,) (CC and) (NP (NP (CD 4.48) (NNP ±) (CD 16.65)) (PP (IN vs.) (NP (NP (CD 57.63) (JJ ±) (CD 65.47) (NNS mg)) (PP (IN at) (NP (CD 48) (NN h)))))) (: ;) (NP (NP (NNP P) (NNP <)) (NP (CD 0.001)))))) (-RRB- -RRB-))))) (. .))) |ET| |BV| 1:-0.9888184666633606 2:-0.036411605775356293 3:-0.16726793348789215 4:-0.025435216724872589 5:0.34337225556373596 6:-0.55500167608261108 7:-0.3844161331653595 8:-0.56394279003143311 9:-1.5017604827880859 10:0.49956929683685303 11:0.87537050247192383 12:0.7571071982383728 13:0.16713796555995941 14:-0.89498591423034668 15:-0.89097511768341064 16:-1.0591216087341309 17:-0.011337496340274811 18:-0.058668743818998337 19:-0.46799993515014648 20:0.4204787015914917 21:-0.73722934722900391 22:-1.1519519090652466 23:0.49414089322090149 24:-0.57728129625320435 25:0.3288191556930542 26:-0.37488621473312378 27:0.063054203987121582 28:-0.20931245386600494 29:-0.75818890333175659 30:0.54235333204269409 31:-0.51095908880233765 32:-0.18060749769210815 33:0.72852551937103271 34:-0.926871657371521 35:1.1163361072540283 36:0.34777006506919861 37:-1.2889693975448608 38:-0.81911903619766235 39:-0.083444505929946899 40:-0.019304726272821426 41:-0.056745157 42:-0.10461292 43:-0.23530145 44:0.21881442 45:0.16712166 46:0.49022275 47:0.4913868 48:-0.41780251 49:-0.28526998 50:-0.54872239 51:0.61404914 52:0.084271513 53:0.18436395 54:0.16098043 55:0.1683194 56:0.20285872 57:0.45805579 58:0.46654359 59:0.25946987 60:0.25055411  |EV|
-1 |BT| (ROOT (S (PP (IN Because) (IN of) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB kill) (NP (NNS flies)) (ADVP (ADVP (RBR sooner)) (SBAR (IN after) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN exposed) (S (VP (TO to) (VP (VB flies) (SBAR (WHADVP (WRB when)) (S (NP (NN food)) (VP (VBZ is) (ADJP (JJ present) (CC or) (JJ absent)))))))))))))))))) (, ,) (NP (NP (NN thiamethoxam) (CC or) (NN imidacloprid)) (PP (IN in) (NP (ADJP (JJ sucrose) (CC or) (JJ Nu-Lure)) (NN bait)))) (VP (MD may) (VP (VB reduce) (NP (NP (NNS infestations)) (PP (IN in) (NP (NNS cherries)))) (PP (JJR more) (IN than) (NP (NP (JJ spinosad) (NN bait)) (SBAR (WHADVP (WRB when)) (S (NP (JJ mature) (NNP R.) (NNS indifferens)) (VP (VBP are) (ADJP (JJ present) (PP (IN in) (NP (NNS orchards))))))))))) (. .))) |ET| |BV| 1:-0.9349932074546814 2:-0.84000343084335327 3:-0.41635552048683167 4:-0.3888784646987915 5:-0.25315806269645691 6:-0.15392397344112396 7:0.025107415392994881 8:0.56973457336425781 9:0.38532906770706177 10:0.37857183814048767 11:0.66472488641738892 12:0.96014046669006348 13:0.74786615371704102 14:-0.18957825005054474 15:-0.72223562002182007 16:-0.079844474792480469 17:-0.32539805769920349 18:0.89657247066497803 19:0.50971692800521851 20:0.36139878630638123 21:-1.2632162570953369 22:-0.46057862043380737 23:-0.064442560076713562 24:0.27803933620452881 25:1.824683666229248 26:0.44906333088874817 27:-0.62095379829406738 28:1.3607707023620605 29:0.52368587255477905 30:0.70744872093200684 31:0.14637088775634766 32:0.29800376296043396 33:0.50296157598495483 34:1.1620501279830933 35:-0.66116088628768921 36:0.95227128267288208 37:-1.4709150791168213 38:0.78650617599487305 39:0.57909804582595825 40:-0.23994192481040955 41:-0.2052425 42:-0.2935701 43:0.17362514 44:-0.13440734 45:0.19157575 46:0.26613486 47:0.12209848 48:-0.41890728 49:0.39466119 50:0.24509606 51:0.2233882 52:0.05254088 53:0.096275628 54:-0.033850063 55:0.025151137 56:0.25679129 57:0.043408301 58:-0.36408707 59:0.059258375 60:-0.089160398  |EV|
-1 |BT| (ROOT (S (PP (IN In) (NP (JJ cost-effectiveness) (NNS analyses))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NN enoxaparin)))) (, ,) (NP (NN rivaroxaban)) (VP (VBD showed) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB reduce) (NP (NP (NNS costs)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN prophylaxis) (CC and) (NN treatment)) (PP (IN of) (NP (NP (JJ thromboembolic) (NNS events)) (PP (IN in) (NP (DT a) (JJ post-orthopedic) (NN surgery/arthroplasty) (NN population)))))))))))))) (. .))) |ET| |BV| 1:-0.63687938451766968 2:-0.82367885112762451 3:-0.065637841820716858 4:-0.35780254006385803 5:0.60219275951385498 6:-0.13255666196346283 7:-0.33090624213218689 8:-0.14652448892593384 9:0.76032280921936035 10:0.47847583889961243 11:0.054607506841421127 12:1.1422563791275024 13:0.020491387695074081 14:-1.2595913410186768 15:-0.39662492275238037 16:0.89241385459899902 17:-1.4477484226226807 18:0.89069348573684692 19:-0.64151692390441895 20:-0.7832256555557251 21:-1.7548869848251343 22:-0.14842353761196136 23:0.22197359800338745 24:-0.86632192134857178 25:-0.15915651619434357 26:0.096142105758190155 27:-0.24397246539592743 28:-0.49696773290634155 29:0.98347151279449463 30:-0.27319023013114929 31:0.10538827627897263 32:1.4941284656524658 33:-0.53808337450027466 34:-0.85002756118774414 35:-0.11465001106262207 36:-0.76051294803619385 37:-0.4002736508846283 38:-0.27437341213226318 39:-0.3136385977268219 40:-1.174877405166626 41:0.30643642 42:0.83468443 43:-0.42223439 44:-0.02609954 45:0.26689458 46:-0.096936002 47:0.35998362 48:-0.4658424 49:0.13743313 50:-0.069458447 51:0.71144104 52:0.15474622 53:0.021676766 54:-0.2040586 55:0.25782084 56:0.13354297 57:0.62245476 58:0.049976192 59:0.30526611 60:-0.06229981  |EV|
-1 |BT| (ROOT (S (NP (NP (CD One)) (PP (IN of) (NP (NP (DT the) (NNS compounds)) (PRN (-LRB- -LRB-) (NP (NN itraconazole)) (-RRB- -RRB-))))) (VP (VBD had) (NP (DT a) (NN recovery)) (ADVP (RBR lower)) (SBAR (IN than) (S (NP (NP (CD 10) (NN %)) (CC and) (NP (NN nystatin))) (VP (VBD was) (RB not) (VP (VBN detected)))))) (. .))) |ET| |BV| 1:0.1678144782781601 2:-0.52809464931488037 3:-0.12842898070812225 4:0.34845629334449768 5:-0.63627457618713379 6:0.71738648414611816 7:0.53563845157623291 8:-0.20069080591201782 9:-1.2866861820220947 10:-0.43386229872703552 11:-0.74856692552566528 12:0.89637339115142822 13:-0.023104120045900345 14:-0.77587366104125977 15:0.10867280513048172 16:-0.37773069739341736 17:-0.0044441232457756996 18:0.38815218210220337 19:-0.47265633940696716 20:-0.47911813855171204 21:-1.0342167615890503 22:-0.51203769445419312 23:0.070500165224075317 24:-0.16789917647838593 25:-0.02841765433549881 26:-0.23923087120056152 27:0.24863159656524658 28:0.95713514089584351 29:-1.0422115325927734 30:-0.32936185598373413 31:-0.82208013534545898 32:0.74385029077529907 33:-1.1902779340744019 34:-0.13556532561779022 35:0.47784367203712463 36:-0.64024978876113892 37:-0.044787149876356125 38:0.13334040343761444 39:-0.20442131161689758 40:-0.41717678308486938 41:0.018862264 42:-0.11027367 43:-0.38756818 44:0.29120824 45:-0.11288218 46:-0.20460065 47:-0.16996035 48:-0.055094656 49:-0.23952611 50:-0.18647541 51:-0.016213369 52:0.096646249 53:-0.062678933 54:-0.30704036 55:0.093983792 56:-0.22230142 57:0.2064351 58:0.22655106 59:0.082386993 60:-0.12704848  |EV|
-1 |BT| (ROOT (S (S (NP (NP (NNS Lynxes)) (VP (VBN captured) (PP (IN in) (NP (DT the) (JJ wild))))) (VP (VBD had) (NP (NP (JJR higher) (NNS concentrations)) (PP (IN of) (NP (NN iron) (, ,) (NN calcium) (, ,) (JJ alkaline) (NN phosphatase) (CC and) (NN creatinine)))))) (, ,) (CC but) (S (NP (NP (JJR lower) (NN aspartate)) (ADJP (JJ aminotransferase) (CC and) (JJ alanine))) (VP (VBP aminotransferase) (PP (IN than) (NP (NP (NNS lynxes)) (VP (VBN maintained) (PP (IN in) (NP (NN captivity)))))))) (. .))) |ET| |BV| 1:-0.76733154058456421 2:0.24607940018177032 3:-0.3637290894985199 4:-0.26238524913787842 5:-0.33067521452903748 6:-0.33500140905380249 7:-0.08953440934419632 8:0.13414254784584045 9:0.37700408697128296 10:0.26008978486061096 11:-0.075949981808662415 12:-0.24670501053333282 13:0.17961160838603973 14:-0.15187470614910126 15:-1.0580264329910278 16:-0.25400683283805847 17:-0.31937047839164734 18:0.033552780747413635 19:0.48308485746383667 20:-0.69982004165649414 21:-0.21283119916915894 22:0.29001902043819427 23:0.68295510113239288 24:-0.6740993857383728 25:-1.1352971196174622 26:-0.98381966352462769 27:-0.22577196918427944 28:1.3822951316833496 29:-0.33825018722563982 30:0.011160446330904961 31:-0.21373241394758224 32:0.52048571407794952 33:0.17308099567890167 34:-0.055090829730033875 35:-0.16623029857873917 36:-0.88049033284187317 37:-0.43777583539485931 38:0.43452773243188858 39:0.70160439610481262 40:-1.3682826161384583 41:-0.14502551 42:0.079374112 43:0.19454043 44:0.22695564 45:0.071411297 46:0.30534536 47:-0.30067673 48:-0.3774156 49:-0.25799051 50:-0.075467892 51:0.16250622 52:-0.06066801 53:-0.17404659 54:-0.53735971 55:0.42052585 56:0.24033782 57:-0.0161146 58:0.13624333 59:-0.27475718 60:0.26492697  |EV|
-1 |BT| (ROOT (S (NP (DT This) (NN subgroup) (NN analysis)) (VP (VBD assessed) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NN duloxetine)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ chronic) (JJ low) (NN back) (NN pain)) (PRN (-LRB- -LRB-) (NP (NNP CLBP)) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD did)) (CC or) (VP (VBD did) (RB not) (VP (VB use) (NP (NP (NP (JJ concomitant) (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP NSAIDs)) (-RRB- -RRB-))) (CC or) (NP (NP (NN acetaminophen)) (PRN (-LRB- -LRB-) (NP (NNP APAP)) (-RRB- -RRB-)))))))))))))) (. .))) |ET| |BV| 1:-0.27432116866111755 2:-0.33306565880775452 3:-0.36629128456115723 4:0.16390925645828247 5:0.046925179660320282 6:0.30733785033226013 7:-0.15638004243373871 8:-0.22471505403518677 9:0.75203102827072144 10:-0.44779619574546814 11:-0.51371639966964722 12:0.43845212459564209 13:-0.0054490123875439167 14:-0.7329288125038147 15:-0.44580641388893127 16:-0.074879013001918793 17:-0.10427278280258179 18:-0.67266559600830078 19:0.51986104249954224 20:-0.36629292368888855 21:-0.30019044876098633 22:0.4576566219329834 23:-0.72681111097335815 24:0.26726287603378296 25:-0.46150615811347961 26:0.22447872161865234 27:-0.0065002832561731339 28:-1.3609868288040161 29:0.63409930467605591 30:0.48830804228782654 31:0.15883137285709381 32:0.39654827117919922 33:-0.92996996641159058 34:-0.14219874143600464 35:0.33372294902801514 36:0.70009976625442505 37:-1.1592376232147217 38:-0.20542705059051514 39:-1.2482024431228638 40:-1.9924114942550659 41:-0.21710891 42:0.017492415 43:-0.077951431 44:-0.1244962 45:-0.28232586 46:0.031896763 47:0.13165213 48:-0.34964558 49:0.16077699 50:-0.045901164 51:0.56965244 52:0.64295387 53:0.22851603 54:0.55944812 55:0.22342868 56:0.0025534863 57:0.21742606 58:0.15235163 59:0.34077328 60:-0.17663848  |EV|
-1 |BT| (ROOT (S (NP (DT These) (NNS changes)) (VP (VBD were) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NN copper) (CC and) (NN increase))))))) (PP (IN in) (NP (NP (DT the) (NNS contents)) (PP (IN of) (NP (NN iron) (CC and) (NN zinc))))))) (. .))) |ET| |BV| 1:0.11782391369342804 2:-0.1132638230919838 3:-0.45559829473495483 4:0.2364472895860672 5:0.76049387454986572 6:-0.59329843521118164 7:0.54228013753890991 8:0.41613417863845825 9:0.04001135379076004 10:-0.32132768630981445 11:0.92303711175918579 12:0.70906955003738403 13:-0.073625802993774414 14:0.061595749109983444 15:0.56586366891860962 16:0.75466644763946533 17:-0.81484872102737427 18:-0.17582589387893677 19:0.64058375358581543 20:-0.051477093249559402 21:-0.74884217977523804 22:0.18795172870159149 23:-0.35792919993400574 24:-0.39937427639961243 25:0.29393559694290161 26:0.055640600621700287 27:-0.16449184715747833 28:0.54225575923919678 29:-0.17021761834621429 30:0.46019065380096436 31:-0.34636086225509644 32:0.68233990669250488 33:0.22303614020347595 34:0.37572193145751953 35:0.0026174897793680429 36:0.50201570987701416 37:-0.6518256664276123 38:-0.29110181331634521 39:0.37301832437515259 40:-0.7345922589302063 41:-0.52151436 42:0.36301577 43:0.11519662 44:-0.18627067 45:-0.1429224 46:0.067456037 47:0.040772188 48:-0.32767636 49:0.078148097 50:0.075569674 51:0.27832347 52:-0.27102283 53:-0.10823724 54:0.083492272 55:0.12912029 56:0.07101696 57:0.17244187 58:0.16245534 59:-0.4915095 60:0.28482673  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Routine) (JJ daily) (NN bathing)) (PP (IN of) (NP (NP (JJ intensive) (NN care) (PRN (-LRB- -LRB-) (NP (NNP ICU)) (-RRB- -RRB-)) (NNS patients)) (PP (IN with) (NP (JJ topical) (NN chlorhexidine)))))) (VP (VBZ reduces) (NP (JJ meticillin-resistant) (JJ Staphylococcus) (NN aureus) (PRN (-LRB- -LRB-) (NP (NNP MRSA)) (-RRB- -RRB-)) (NN acquisition))) (. .))) |ET| |BV| 1:-0.38235658407211304 2:-0.35802099108695984 3:-0.92465639114379883 4:-0.1590530127286911 5:0.67977166175842285 6:0.18756574392318726 7:-1.8524057865142822 8:-0.53687405586242676 9:0.1302802711725235 10:-0.17640723288059235 11:0.35672998428344727 12:0.27285945415496826 13:0.37446418404579163 14:-0.34114989638328552 15:0.24039839208126068 16:-0.069708369672298431 17:0.075336895883083344 18:-0.23520103096961975 19:0.35550683736801147 20:-1.7085436582565308 41:0.17285195 42:-0.057957578 43:-0.23464128 44:-0.33174884 45:0.26739672 46:0.14824897 47:-0.16852869 48:0.26936728 49:0.27205941 50:0.16250017 51:0.012166604 52:0.14441533 53:-0.46991572 54:0.22494052 55:-0.19457987 56:0.051394314 57:0.33979556 58:0.047248535 59:-0.20525178 60:-0.24888507  |EV|
